News
Asianet Newsable on MSN52m
AbbVie’s Migraine Drug Yields Positive Outcome In Late-Stage Study Versus Topiramate, But Fails To Draw Retail CheerAtogepant had fewer discontinuations in the study involving 545 participants due to adverse events than Topiramate.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback